Mannan, A Potential Therapeutic for Asthma

描述（由申请人提供）：本申请的长期目标是开发来源于面包酵母的甘露聚糖作为哮喘治疗。目前可用的免疫调节剂的局限性是它们在较高剂量下的毒性和对气道平滑肌（ASM）重塑缺乏有益作用，因此，需要新的连续治疗剂。私家侦探的初步调查结果。的实验室已经表明，来自S.酿酒酵母，一种基于碳水化合物的益生元聚甘露糖剂，抑制气道炎症、高反应性（AHR）和ASM重塑。我们的中心假设是S.酿酒酵母是一种新型的免疫调节剂，抑制ASM重塑。建议进行以下研究：1）确定甘露聚糖鼻内给药的最佳剂量和给药时间。2)确定甘露聚糖口服给药的最佳剂量和给药时间。田纳西大学医学院儿科过敏/免疫学系和坎伯兰新兴技术公司（CET），坎伯兰制药公司（CPI）的子公司，正在合作确定和开发有前途的治疗和预防哮喘的药物疗法。私家侦探将进行提案中概述的临床前研究，CET将开发用于临床前和临床试验的产品。从这些研究中获得的知识将提供一类新型的哮喘调整疗法，该疗法将调节ASM重塑，并将产生一种独特的鼻内和口服产品，使哮喘患者和患有其他相关疾病的患者受益。公共卫生相关性：我们的中心假设是来自S。酿酒酵母是一种新型的免疫调节剂，抑制ASM重塑。本申请的长期目标是开发来自面包酵母的甘露聚糖作为哮喘治疗。

DESCRIPTION (provided by applicant): The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy. The limitations of currently available immunomodulators are their toxicity at higher doses and the lack of beneficial effect on airway smooth muscle (ASM) remodeling and therefore, new adjunctive therapeutics are needed. Initial findings in the P.I.'s laboratory have shown that mannan from S. cerevisiae, a carbohydrate-based prebiotic polymannose agent, inhibits airway inflammation, hyperreactivity (AHR) and ASM remodeling. Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. Studies are proposed 1) to determine the optimum dose and dose timing of mannan administered intranasally. 2) to determine the optimum dose and dose timining of mannan administered orally. The University of Tennessee College of Medicine Department of Pediatric Allergy/Immunology and Cumberland Emerging Technologies Inc (CET), an affiliate of Cumberland Pharmaceuticals Inc (CPI), are collaborating to identify and develop promising pharmaceutical therapies for treating and preventing asthma. The P.I. will conduct preclinical studies outlined in the proposal and CET will develop the product for the preclinical and clinical trials. The knowledge gained from these studies will provide a novel class of adjuctive asthma therapy that will modulate ASM remodeling and will lead to a unique intranasal and oral products that will benefit asthmatics and patients with other related diseases. PUBLIC HEALTH RELEVANCE: Our central hypothesis is that mannan from S. cerevisiae is a novel class of immunomodulator that suppresses ASM remodeling. The long-term goal of this application is to develop mannan derived from Baker's yeast as asthma therapy.